The post LTC Price Prediction: Targets $72-80 Recovery by February 2026 appeared on BitcoinEthereumNews.com. Peter Zhang Jan 22, 2026 16:06 LTC Price PredictionThe post LTC Price Prediction: Targets $72-80 Recovery by February 2026 appeared on BitcoinEthereumNews.com. Peter Zhang Jan 22, 2026 16:06 LTC Price Prediction

LTC Price Prediction: Targets $72-80 Recovery by February 2026



Peter Zhang
Jan 22, 2026 16:06

LTC Price Prediction Summary • Short-term target (1 week) : $68-70 range with volatility • Medium-term forecast (1 month) : $72-80 recovery zone • Bullish breakout level : $71.64 (strong…

LTC Price Prediction Summary

Short-term target (1 week): $68-70 range with volatility
Medium-term forecast (1 month): $72-80 recovery zone
Bullish breakout level: $71.64 (strong resistance)
Critical support: $64.28 (strong support zone)

What Crypto Analysts Are Saying About Litecoin

Recent analyst commentary on Litecoin’s price action has been measured but cautiously optimistic. According to Terrill Dicki’s analysis from January 16, 2026, “Litecoin trades at $72.20 with oversold RSI at 33.44. Technical analysis suggests LTC could rebound to $80-85 resistance zone within 3-4 weeks if key support holds at $68.80.”

DigitalCoinPrice has provided detailed short-term forecasts showing mixed signals for the coming week, with their LTC price prediction indicating potential volatility through January 29, with prices ranging from $65.28 to $69.77.

While specific analyst predictions are limited, on-chain data from major platforms suggests Litecoin is currently experiencing oversold conditions that historically precede price recoveries.

LTC Technical Analysis Breakdown

Litecoin’s current technical picture presents a compelling oversold scenario. Trading at $68.15, LTC has declined 1.25% in the past 24 hours, with the price action occurring within a $66.03-$69.71 range.

The RSI reading of 32.74 places Litecoin in neutral-to-oversold territory, suggesting selling pressure may be nearing exhaustion. This RSI level often coincides with potential reversal points in LTC’s price history.

MACD analysis shows bearish momentum with a reading of -3.0573, though the histogram at -0.0000 suggests the bearish momentum may be stalling. The convergence of MACD lines often precedes directional changes.

Bollinger Band positioning reveals LTC trading near the lower band with a %B position of 0.0927, indicating the asset is approaching oversold conditions. The lower band sits at $66.18, providing technical support, while the middle band at $76.82 represents the first major resistance.

The Average True Range (ATR) of $4.13 indicates moderate volatility, suggesting price movements of approximately $4 can be expected in either direction during normal trading sessions.

Litecoin Price Targets: Bull vs Bear Case

Bullish Scenario

The bullish case for this LTC price prediction centers on the current oversold conditions and technical support levels. If Litecoin can maintain support above $66.22, the path opens toward the immediate resistance at $69.90.

A break above the strong resistance at $71.64 would signal the beginning of a broader recovery, targeting the 20-day SMA at $76.82. The ultimate bullish target aligns with analyst projections of $80-85, representing a 17-25% upside from current levels.

Key confirmation signals include RSI moving above 40, MACD histogram turning positive, and sustained volume above the recent average of $43.7 million.

Bearish Scenario

The bearish scenario for this Litecoin forecast would unfold if support at $66.22 fails to hold. A breakdown below this level could trigger selling toward the strong support zone at $64.28.

Further weakness could see LTC testing the psychological $60 level, representing a 12% decline from current prices. The bearish case would be confirmed by RSI dropping below 30, increased selling volume, and a widening negative MACD histogram.

Risk factors include broader crypto market weakness, regulatory concerns, and potential Bitcoin correlation dragging altcoins lower.

Should You Buy LTC? Entry Strategy

Based on current technical levels, the optimal entry strategy for Litecoin involves waiting for confirmation signals. Conservative buyers should consider accumulating near the $66-67 support zone with a stop-loss below $64.

Aggressive traders might enter at current levels around $68, targeting the $72-76 resistance zone for a potential 12% gain. However, position sizing should reflect the inherent volatility indicated by the $4.13 ATR.

For risk management, any position should include a stop-loss below $64.28 to limit downside exposure. Take-profit levels should be set at $72 (first target) and $78-80 (extended target) based on the technical resistance levels identified.

Conclusion

This LTC price prediction suggests a cautiously optimistic outlook for Litecoin over the next 3-4 weeks. The combination of oversold RSI conditions, support near Bollinger Band lowers, and analyst targets in the $80-85 range provide a reasonable basis for expecting a recovery.

However, the bearish MACD and position below all major moving averages indicate caution is warranted. The most likely scenario involves consolidation around current levels before a gradual recovery toward $72-80, assuming broader market conditions remain supportive.

Disclaimer: Cryptocurrency price predictions are inherently speculative and based on technical analysis and market conditions that can change rapidly. This analysis should not be considered financial advice, and investors should conduct their own research before making trading decisions.

Image source: Shutterstock

Source: https://blockchain.news/news/20260122-ltc-price-prediction-targets-72-80-recovery-by-february-2026

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

U.S. President Donald Trump filed a lawsuit against JPMorgan Chase and its CEO Jamie Dimon personally, accusing the institution of deliberate debanking. The politician
Share
Incrypted2026/01/23 15:59
Here’s why Polygon price is at risk of a 25% plunge

Here’s why Polygon price is at risk of a 25% plunge

Polygon price continued its freefall, reaching its lowest level since April 21, as the broader crypto sell-off gained momentum. Polygon (POL) dropped to $0.1915, down 32% from its highest point in May and 74% below its 2024 peak. The crash…
Share
Crypto.news2025/06/19 00:56
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26